Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12808319 | 1.00 | KDR (1.00) | KDRFGFR1EGFRERBB2LCK | |
| SCHEMBL1683464 | 0.91 | KDR (0.84) | KDRFGFR1EGFRERBB2LCK | |
| SCHEMBL1683459 | 0.91 | KDR (0.84) | KDRFGFR1EGFRERBB2LCK | |
| SCHEMBL1683433 | 0.86 | KDR (0.76) | KDRFGFR1EGFRERBB2LCK | |
| SCHEMBL1683431 | 0.82 | KDR (1.00) | KDRFGFR1EGFRERBB2LCK | |
| SCHEMBL26928560 | 0.76 | KDR (1.00) | KDRFGFR1EGFRERBB2LCK | |
| SCHEMBL1683420 | 0.71 | KDR (0.72) | KDRFGFR1EGFRLCKPDGFRB | |
| SCHEMBL1683425 | 0.71 | KDR (0.72) | KDRFGFR1EGFRLCKPDGFRB | |
| SCHEMBL1683443 | 0.67 | KDR (0.61) | KDRFGFR1EGFRERBB2LCK | |
| SCHEMBL1683428 | 0.67 | KDR (0.51) | KDRFGFR1EGFRERBB2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539763-B1 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | claimed |
| EP-1539763-B1 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | disclosed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063707-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | KDR 5/4885FGFR1 1/4885EGFR 43/4885 |
| US-20060058304-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | KDR 5/4885FGFR1 1/4885EGFR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.